Table 4.
Exploratory outcomes
| PE | E | ΔE | PI | I | ΔI | ΔT | |
|---|---|---|---|---|---|---|---|
| MR day 1 | |||||||
| Central blood volume (L) | 1077 ± 58 | 1026 ± 74 | −45 ± 67 | 1132 ± 67 | 1094 ± 57 | −29 ± 43 | −61 ± 60 |
| Left ventricular end-diastolic volume (mL) | 163 ± 10 | 160 ± 11 | −4 ± 6 | 166 ± 10 | 164 ± 10 | −3 ± 3 | −4 ± 5 |
| Cardiac output Stress (L/min) | 6.52 ± 0.38 | 6.23 ± 0.29 | −0.48 ± 0.24 | 6.24 ± 0.33 | 6.68 ± 0.29 | 0.30 ± 0.21 | −0.51 ± 0.23* |
| LV myocardial mass (g/m2) | 65 ± 4 | 66 ± 4 | 0 ± 2 | 65 ± 4 | 65 ± 4 | 0 ± 2 | 0 ± 1 |
| Pro-ANP (pmol/L) | 405 ± 67 | 340 ± 54 | −65 ± 26* | 419 ± 65 | 427 ± 68 | 8 ± 23 | −86 ± 27** |
| 24-h ambulatory blood pressure monitoring | |||||||
| Systolic BP (mmHg) | 130.2 ± 2.8 | 130.1 ± 1.5 | 0.9 ± 2.7 | 130.9 ± 3.6 | 134.9 ± 3.1 | 3.9 ± 3.4 | −4.7 ± 3.2 |
| Diastolic BP (mmHg) | 76.9 ± 1.8 | 77.41 ± 1.7 | 1.8 ± 1.4 | 78.4 ± 2.5 | 79.2 ± 1.9 | 1.0 ± 2.3 | −0.9 ± 1.6 |
| 24-h pulse pressure product (mmHg x min−1) | 9679 ± 341 | 10,032 ± 354 | 402 ± 235 | 9810 ± 414 | 10149 ± 433 | 482 ± 277 | −223 ± 305 |
| Metabolic study day | |||||||
| VO2max (ml/kg) | 14 ± 0.7 | 14 ± 0.7 | 0.1 ± 0.5 | 16 ± 1 | 14 ± 0.7 | −1.7 ± 0.4† | 0.0 ± 0.7 |
| Glucagon (pmol/L) | 18 ± 1 | 19 ± 1 | 0 ± 1 | 19 ± 1 | 19 ± 1 | 1 ± 1 | 0 ± 1 |
Data are presented as Mean ± SEM
PE Pre-Empagliflozin, E Empagliflozin, PI Pre-Insulin, I Insulin, ΔE E-PE, ΔI I-PI, ΔT E-I
*p < 0.05; **p < 0.01. †p < 0.05 vs ΔE